Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes
- 18 August 2021
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 107 (6) , 609-616
Abstract
Objectives The presence of targeted therapy, Enasidenib, for IDH2-mutated AML underscores the importance of understanding the clonal dynamics of IDH2 mutations, which has not been elucidated. In the largest study of IDH2 clonal dynamics, we detail the IDH2-evolutionary patterns and their clinical significance. Methods We analyzed ~6000 patients with NGS results to identify 120 AML patients with IDH2 mutations and longitudinal NGS testing. IDH2 mutation status was recorded at diagnosis, remission, relapse, and persistent disease. Results One hundred and five patients were IDH2-positive at the initial diagnosis, and 15 acquired the mutation later. Of those 15 patients, 7 patients gained the mutation during persistent disease, 6 during relapse, and 2 at remission. Twenty-one patients (18%) who were IDH2-positive in a prior test remained IDH2-positive in remission. Twenty-four patients with IDH2-positive AML were IDH2-positive at relapse. IDH2-positive at diagnosis had better survival than IDH2 mutation acquired later in disease (P = .024). Patients who were IDH2-negative in remission had significantly improved survival (P = .002). Also, loss-of-IDH2 mutation with persistent disease had better OS (P = .035). Conclusions There are 70% that clear IDH2 in disease remission. 12% gain IDH2 mutation later, usually in the setting of refractory/relapsed AML. These patients fared worse. Longitudinal IDH2 testing may be helpful in prognostic stratification.Keywords
This publication has 32 references indexed in Scilit:
- Acute myeloid leukemia: 2013 update on risk‐stratification and managementAmerican Journal of Hematology, 2013
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Acute Myeloid Leukemia With IDH1 or IDH2 MutationAmerican Journal of Clinical Pathology, 2011
- The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemiaLeukemia, 2010
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemiaBlood, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsJournal of Experimental Medicine, 2010
- Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010Annals of Oncology, 2009
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999